ㆍDAILY PROGRAMㆍPROGRAM AT A GLANCE

DAILY PROGRAM

08:30-09:30

Symposium 3-1. Occult Hepatitis Virus Infection and Post-Cure Virologic Failure

  • 08:30-08:45

  • Occult Hepatitis B Virus Infection: the Fate and Clinical Implications

  • 08:45-09:00

  • Threat: Hepatitis B Virus Reactivation after Resolved Hepatitis B

  • 09:00-09:15

  • A Twist to a Cure of Hepatitis C Virus Infection: Occult Hepatitis C Virus Infection

  • 09:15-09:30

  • Re-Infection of Hepatitis C Virus Post-SVR

09:30-10:30

Symposium 3-3. What Happens (remains) in the Liver During the Cure of Viral Hepatitis?

  • 09:30-09:45

  • Changes in the Transcriptional Activity of Intrahepatic cccDNA and Integrated Hepatitis B Virus DNA

  • 09:45-10:00

  • Surrogate Indicators of Intrahepatic cccDNA Pool and Integrated Hepatitis B Virus DNA

  • 10:00-10:15

  • Intrahepatic and Extrahepatic Trace of Hepatitis C Virus after SVR: Mechanisms and Clinical Implications

  • 10:15-10:30

  • Metabolomic Changes after SVR to DAA in Chronic Hepatitis C Patients

  • 10:30-10:50

  • Coffee Break

10:50-11:20

State-of-the-Art Lecture 3. A Roadmap to Eliminating Hepatitis: Viral or Non-viral

  • 10:50-11:20

  • Elimination of Viral Hepatitis: Achievements, Challenges, and Prospects

11:20-12:00

Special Symposium (Wrap-up)

  • 12:00-12:30

  • Closing & Awarding Ceremony

09:30-10:30

Symposium 3-4. Precision Medicine for the Cure of Viral Liver Disease

  • 09:30-09:45

  • Personalized Management of Viral Hepatitis of the Present and the Future

  • 09:45-10:00

  • Risk Stratification for HCC in Chronic Hepatitis B: A Promise for Precision Medicine

  • 10:00-10:15

  • Host and Genetic Factors for Precision Medicine Toward a Cure of Viral Hepatitis

  • 10:15-10:30

  • Biomarker Discovery and Application for Liver Disease in the Era of Precision Medicine

07:30-08:20

Early Morning Workshop 3. Real-life Experiences for NUCs against CHB

  • 07:30-07:50

  • Fibrosis Regression after NUC Treatment in CHB and Related Mechanisms

  • 07:50-08:10

  • Adverse Effects of Nucleos(t)ide Analogue Treatment and Ways to Reverse It

  • 08:10-08:20

  • Discussion

07:30-08:20

Early Morning Workshop 4. Screening and Prognosis of Hepatitis D Virus Infection with Case Discussion

  • 07:30-07:50

  • Who Should Be Screened for Hepatitis D Virus Infection?

  • 07:50-08:10

  • Prognosis of Untreated Hepatitis D Virus Infection

  • 08:10-08:20

  • Discussion